High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1850-1856

  de Lastours, Victoire ^a   De Silva, Erika Ferrari Rafael ^a   Daudon, Michel ^b   Porcher, Raphaé ^a   Loze, Benedicte ^a   Sauvageon, Helene ^a   Molina, Jean Michel ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c INSERM   (France)

Author keywords

Antiretrovirals; HIV drug toxicity; Urolithiasis

Indexed keywords

ATAZANAVIR; DARUNAVIR; LOPINAVIR; RITONAVIR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; CRYSTALLURIA; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; TREATMENT DURATION;

ANTIRETROVIRALS; HIV DRUG TOXICITY; UROLITHIASIS;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; CRYSTALLIZATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICROSCOPY, POLARIZATION; MIDDLE AGED; OLIGOPEPTIDES; PLASMA; PYRIDINES; SULFONAMIDES; URINE; YOUNG ADULT;

EID: 84880753556     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt125     Document Type: Article

References (18)

1. Reyataz (Atazanavir Sulfate): Full Prescription Information (Package Insert). Princeton, NJ: Bristol-Myers Squibb, 2012.
2. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9.
3. Pavie J, Porcher R, Torti C et al. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother 2011; 66: 2372-8.
4. Molina J-M, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir andemtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-32.
5. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
6. Pacanowski J, Poirier J-M, Petit I et al. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006; 20: 2131.
7. Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med 2006; 355:2158-9.
8. Chan-Tack KM, Truffa MM, Struble KA et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21: 1215-8.
9. Rockwood N, Mandalia S, Bower M et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavirboosted darunavir. AIDS 2011; 25: 1671-3.
10. Anderson PL, Lichtenstein KA, Gerig NE et al. Atazanavir-containing renal calculi in an HIV-infected patient. AIDS 2007; 21: 1060-2.
11. Hamada Y, Nishijima T, Watanabe K et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55: 1262-9.
12. Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 2004; 64: 245-75.
13. Kopp JB, Miller KD, Mican JA et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119-25.
14. Dieleman JP, Gyssens IC, van der Ende ME et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-8.
15. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneousdetermination of existing and new antiretroviral compounds. J Chromatogr B Analyt TechnolBiomed Life Sci 2010; 878: 1455-65.
16. Couzigou C, Daudon M, Meynard JL et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007; 45: e105-8.
17. Fabbiani M, Bracciale L, Doino M et al. Tenofovir discontinuation could predisposeto urolithiasis in atazanavir-treated patients. J Infect 2011; 62: 319-21.
18. Doco-Lecompte T, Garrec A, Thomas L et al. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004; 18: 705-6.